EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer

Xin Xue iD, Xiao Chen, Yitian Jiang, Xinhai Wang, Zheng Xu, Chenqi Bei, Guanqiao Shi, Yifan Zhu, Yuqing Wei, Yao Chen iD, Nianguang Li iD

Medicinal Research Reviews · 2026

DOI: 10.1002/med.70057 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2026. Verfasst von Xin Xue und 10 weiteren Autor:innen. Beteiligte Einrichtung: National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collab…. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Cell Cycle Proteins, Neoplasms, Synthetic Lethal Mutations. Die Arbeit nennt 246 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Wee kinases, including Wee1, Myt1 (PKMYT1) and Wee2, serve as critical regulators of the DNA damage response by inhibiting the G2/M transition and have attracted increasing attention as a targetable vulnerability in TP53‐deficient cancers. Wee1 is the fastest progressing member in clinical research, and its inhibitors such as AZD‐1775 and ZN‐c3 are under clinical evaluation. Because toxicity and resistance persist with existing agents, research is moving toward newer strategies such as protein degradation technologies. Proceeding from sequence and structure, we, for the first time, use chemoinformatics to delineate the chemical space of the Wee1 binding pocket and classify reported inhibitors into three pocket engagement types, thereby constructing a high‐resolution pocket map and an anchorable Markush for designing inhibitors with high selectivity and activity. We further summarize design principles for targeted degradation of Wee1 and outline combination strategies grounded in synthetic lethality, and we curate recent preclinical and ongoing clinical advances with discussion of biomarker‐guided enrollment and dosing schedules. By linking structural mechanisms to pharmacology and clinical placement, this review provides an actionable framework for next‐generation Wee1‐directed drug design and translation in oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesCell Cycle ProteinsNeoplasmsSynthetic Lethal MutationsMolecular Targeted TherapyHumansProtein Kinase InhibitorsAnimalsAntineoplastic Agents

Stichwörter der Autor:innen

Wee1cancer/tumorschemical spaceclinical advancessynthetic lethality

Substanzen

Protein-Tyrosine KinasesCell Cycle ProteinsWEE1 protein, humanProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrializa…
  • Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
  • Washington University School of Medicine, St. Louis, Missouri, USA.
  • School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.

ORCID-Profile: Xin Xue, Yao Chen, Nianguang Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xue, X., Chen, X., Jiang, Y., Wang, X., Xu, Z., Bei, C., Shi, G., Zhu, Y., Wei, Y., Chen, Y., & Li, N. (2026). A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer. Medicinal Research Reviews. https://doi.org/10.1002/med.70057

Vancouver

Xue X, Chen X, Jiang Y, Wang X, Xu Z, Bei C, et al. A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer. Medicinal Research Reviews. 2026. doi:10.1002/med.70057

BibTeX
@article{Xue2026,
  author = {Xue, Xin and Chen, Xiao and Jiang, Yitian and Wang, Xinhai and Xu, Zheng and Bei, Chenqi and Shi, Guanqiao and Zhu, Yifan and Wei, Yuqing and Chen, Yao and Li, Nianguang},
  title = {A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer},
  journal = {Medicinal Research Reviews},
  year = {2026},
  doi = {10.1002/med.70057}
}
Kostenlos starten →